Galderma Announces Completion of Phase 3 Trials of Investigational Drug Targeting Facial Erythema of Rosacea

Galderma Laboratorie announced the completion of two independent Phase III clinical trials that evaluated the efficacy and safety of CD07805/47, a proprietary topical gel under investigation in adults with moderate to severe facial erythema (redness) of rosacea.
MarketWatch